News Search Results
May 07, 2026, 20:30 ET Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87
China, May 7, 2026 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that the Center for Drug Evaluation of China's
More news about: Chance Pharmaceuticals
May 07, 2026, 17:38 ET INVESTOR DEADLINE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.The Medpace class action lawsuit alleges that defendants throughout the
More news about: Robbins Geller Rudman & Dowd LLP
May 07, 2026, 16:15 ET Nektar Therapeutics Reports First Quarter 2026 Financial Results
information and a PIN allowing them to access the live call.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
May 07, 2026, 16:06 ET Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
May 07, 2026, 16:05 ET Tyra Biosciences to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
May 07, 2026, 16:05 ET Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
bench to autonomous research infrastructure that runs 24/7 and integrates directly with the AI models transforming drug discovery and industrial biotechnology."Recent Business Highlights & Strategic PositioningWe believe that autonomous labs will replace the bench.
More news about: Ginkgo Bioworks
May 07, 2026, 16:01 ET AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
May 07, 2026, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
and 2Q 2027, respectively.About Kodiak Sciences Inc.Kodiak Sciences (Nasdaq: KOD) is a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design
More news about: Kodiak Sciences Inc.
May 07, 2026, 11:19 ET Abu Dhabi Opens Its 'Living Lab' to the World to Accelerate the Future of Health
empowered by deep capital reserve."On the sidelines of the conference, Al Mansoori also met with a select group of leaders in longevity, AI, biotechnology, paediatrics, genomics and investment during a dinner hosted under the Future Health – A Global Initiative by Abu Dhabi platform. The discussion
More news about: The Department of Health - Abu Dhabi
May 07, 2026, 11:08 ET Abu Dhabi Opens Its 'Living Lab' to the World to Accelerate the Future of Health
empowered by deep capital reserve."On the sidelines of the conference, Al Mansoori also met with a select group of leaders in longevity, AI, biotechnology, paediatrics, genomics and investment during a dinner hosted under the Future Health – A Global Initiative by Abu Dhabi platform. The discussion
More news about: The Department of Health - Abu Dhabi
May 07, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
$14 billion. As The Wall Street Journal observed in January 2026, "[f]or context, only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value; the index doesn't include Regencell." At all relevant times, Defendants downplayed the likelihood and severity
More news about: Pomerantz LLP
May 07, 2026, 09:00 ET Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
standard for rapid, large-volume subcutaneous delivery, and underscores the value it provides to a growing number of leading pharmaceutical and biotechnology companies. Extending use of ENHANZE with ADCs represents a meaningful expansion of our potential addressable market, positions us at the forefront
More news about: Halozyme Therapeutics, Inc.
May 07, 2026, 09:00 ET Silicon Valley Bank Expands Life Science & Healthcare Team
Ryan Martin, Director for the NorCal Biotechnology, Diagnostics, and Tools Relationship Management Team, based in San Francisco.
More news about: Silicon Valley Bank
May 07, 2026, 09:00 ET ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Clinical Trial Results: SueWallSt
reproxalap would perform as represented"This case presents important questions about clinical trial disclosure obligations in the biotechnology sector. When a company repeatedly characterizes its trial results as 'consistent' while the FDA later identifies serious inconsistencies, investors
More news about: SueWallSt.com
May 07, 2026, 08:00 ET Repertoire Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201
CAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the U.S. Food and Drug Administration
More news about: Repertoire Immune Medicines
May 07, 2026, 07:17 ET Persistent Achieves Databricks Brickbuilder Specialization for Healthcare & Life Sciences, Expanding Production-Ready Data and AI Solutions For Regulated Environments
AI solutions on the Databricks Data Intelligence platform. It strengthens the Company's position in enabling providers, payers, pharmaceutical, biotechnology and medical device organizations to accelerate clinical development, improve patient outcomes and operationalize AI across regulated environments.
More news about: Persistent Systems
May 07, 2026, 07:10 ET Persistent Achieves Databricks Brickbuilder Specialization for Healthcare & Life Sciences, Expanding Production-Ready Data and AI Solutions For Regulated Environments
AI solutions on the Databricks Data Intelligence platform. It strengthens the Company's position in enabling providers, payers, pharmaceutical, biotechnology and medical device organizations to accelerate clinical development, improve patient outcomes and operationalize AI across regulated environments.
More news about: Persistent Systems
May 07, 2026, 07:05 ET REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
www.regenxbio.com.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered
More news about: REGENXBIO Inc.
May 07, 2026, 07:00 ET TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer and Evolves Leadership for Next Phase of Growth
ANGELES, May 7, 2026 /PRNewswire/ -- TORL BioTherapeutics LLC (TORL), a clinical stage oncology focused biotechnology company, today announced a leadership transition to position the Company for its next phase of growth. Effective as of May 1, 2026, Aran Maree,
More news about: TORL Biotherapeutics LLC
May 07, 2026, 07:00 ET Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
May 07, 2026, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
long-term impact in NSCLC and beyond. Through these efforts, we believe we are well positioned to realize our vision of becoming a sustainable biotechnology company capable of designing, developing and delivering precisely targeted therapies for patients with cancer."Recent Pipeline
More news about: Nuvalent, Inc.
May 07, 2026, 06:27 ET Multi Investment accelerates its diversification strategy following a CHF 480 million capital raise
its scope into high-potential, innovation-driven sectors. Target areas include fintech, deep tech, healthcare, blockchain and Web3, as well as biotechnology. This strategic direction reflects a clear objective: to anticipate major global economic and technological shifts while supporting high
More news about: Multi Investment
May 07, 2026, 06:25 ET Multi Investment accelerates its diversification strategy following a CHF 480 million capital raise
into high-potential, innovation-driven sectors. Target areas include fintech, deep tech, healthcare, blockchain and Web3, as well as biotechnology. This strategic direction reflects a clear objective: to anticipate major global economic and technological shifts while supporting high
More news about: Multi Investment
May 07, 2026, 05:29 ET 2025-26 के लिए HKU ने Entrance Scholarships Award Ceremony आयोजित की
व्यक्त की।बांग्लादेश की Belt and Road Scholarship प्राप्तकर्ता और विज्ञान स्नातक की छात्रा, Naziba Sayem, ने HKU में Molecular Biology and Biotechnology के अध्ययन के पीछे प्रेरणा के रूप में एक दुर्लभ ऑटोइम्यून रोग से जूझने में अपनी मां की सहनशीलता पर प्रकाश डाला। आर्थिक तंगी के बावजूद, उनके माता-पिता
More news about: The University of Hong Kong (HKU)
May 06, 2026, 23:29 ET Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation
CAMBRIDGE, Mass., May 6, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Josh Xiao as Chief Scientific
More news about: Nona Biosciences